1,555 research outputs found
Far Infrared and Submillimeter Emission from Galactic and Extragalactic Photo-Dissociation Regions
Photodissociation Region (PDR) models are computed over a wide range of
physical conditions, from those appropriate to giant molecular clouds
illuminated by the interstellar radiation field to the conditions experienced
by circumstellar disks very close to hot massive stars. These models use the
most up-to-date values of atomic and molecular data, the most current chemical
rate coefficients, and the newest grain photoelectric heating rates which
include treatments of small grains and large molecules. In addition, we examine
the effects of metallicity and cloud extinction on the predicted line
intensities. Results are presented for PDR models with densities over the range
n=10^1-10^7 cm^-3 and for incident far-ultraviolet radiation fields over the
range G_0=10^-0.5-10^6.5, for metallicities Z=1 and 0.1 times the local
Galactic value, and for a range of PDR cloud sizes. We present line strength
and/or line ratio plots for a variety of useful PDR diagnostics: [C II] 158
micron, [O I] 63 and 145 micron, [C I] 370 and 609 micron, CO J=1-0, J=2-1,
J=3-2, J=6-5 and J=15-14, as well as the strength of the far-infrared
continuum. These plots will be useful for the interpretation of Galactic and
extragalactic far infrared and submillimeter spectra observable with ISO,
SOFIA, SWAS, FIRST and other orbital and suborbital platforms. As examples, we
apply our results to ISO and ground based observations of M82, NGC 278, and the
Large Magellenic Cloud.Comment: 54 pages, 20 figures, accepted for publication in The Astrophysical
Journa
Pilot Study Assessment of Dynamic Vascular Changes in Breast Cancer with Near-Infrared Tomography from Prospectively Targeted Manipulations of Inspired End-Tidal Partial Pressure of Oxygen and Carbon Dioxide
The dynamic vascular changes in the breast resulting from manipulation of both inspired end-tidal partial pressure of oxygen and carbon dioxide were imaged using a 30 s per frame frequency-domain near-infrared spectral (NIRS) tomography system. By analyzing the images from five subjects with asymptomatic mammography under different inspired gas stimulation sequences, the mixture that maximized tissue vascular and oxygenation changes was established. These results indicate maximum changes in deoxy-hemoglobin, oxygen saturation, and total hemoglobin of 21, 9, and 3%, respectively. Using this inspired gas manipulation sequence, an individual case study of a subject with locally advanced breast cancer undergoing neoadjuvant chemotherapy (NAC) was analyzed. Dynamic NIRS imaging was performed at different time points during treatment. The maximum tumor dynamic changes in deoxy-hemoglobin increased from less than 7% at cycle 1, day 5 (C1, D5) to 17% at (C1, D28), which indicated a complete response to NAC early during treatment and was subsequently confirmed pathologically at the time of surgery
Crystallographic structure of ultrathin Fe films on Cu(100)
We report bcc-like crystal structures in 2-4 ML Fe films grown on fcc Cu(100)
using scanning tunneling microscopy. The local bcc structure provides a
straightforward explanation for their frequently reported outstanding magnetic
properties, i.e., ferromagnetic ordering in all layers with a Curie temperature
above 300 K. The non-pseudomorphic structure, which becomes pseudomorphic above
4 ML film thickness is unexpected in terms of conventional rules of thin film
growth and stresses the importance of finite thickness effects in ferromagnetic
ultrathin films.Comment: 4 pages, 3 figures, RevTeX/LaTeX2.0
Spitzer IRS Observations of the Galactic Center: Shocked Gas in the Radio Arc Bubble
We present Spitzer IRS spectra (R ~600, 10 - 38 micron) of 38 positions in
the Galactic Center (GC), all at the same Galactic longitude and spanning
plus/minus 0.3 degrees in latitude. Our positions include the Arches Cluster,
the Arched Filaments, regions near the Quintuplet Cluster, the ``Bubble'' lying
along the same line-of-sight as the molecular cloud G0.11-0.11, and the diffuse
interstellar gas along the line-of-sight at higher Galactic latitudes. From
measurements of the [O IV], [Ne II], [Ne III], [Si II], [S III], [S IV], [Fe
II], [Fe III], and H_2 S(0), S(1), and S(2) lines we determine the gas
excitation and ionic abundance ratios. The Ne/H and S/H abundance ratios are ~
1.6 times that of the Orion Nebula. The main source of excitation is
photoionization, with the Arches Cluster ionizing the Arched Filaments and the
Quintuplet Cluster ionizing the gas nearby and at lower Galactic latitudes
including the far side of the Bubble. In addition, strong shocks ionize gas to
O^{+3} and destroy dust grains, releasing iron into the gas phase (Fe/H ~ 1.3
times 10^{-6} in the Arched Filaments and Fe/H ~ 8.8 times 10^{-6} in the
Bubble). The shock effects are particularly noticeable in the center of the
Bubble, but O is present in all positions. We suggest that the shocks
are due to the winds from the Quintuplet Cluster Wolf-Rayet stars. On the other
hand, the H_2 line ratios can be explained with multi-component models of warm
molecular gas in photodissociation regions without the need for H_2 production
in shocks.Comment: 51 pages, 17 figures To be published in the Astrophysical Journa
Factors affecting distribution and removal rates of small mammals in a lowland swamp forest
High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma.
High-dose ipilimumab (IPI) and high-dose interleukin-2 (IL-2) are approved agents for metastatic melanoma, but the efficacy and safety of the combination are unknown. The objective of this study was to evaluate the feasibility, safety, and efficacy of combination high-dose IPI and high-dose IL-2 in patients with histologically confirmed advanced unresectable stage III and IV melanoma. This Phase II, multicenter, open-label, single-arm trial was conducted in nine patients enrolled between 12/2014 and 12/2015. Subjects were treated with high-dose IPI 10 mg/kg intravenous (IV) every 3 weeks for four doses starting at week 1 and high-dose IL-2 (600,000 IU/kg IV bolus every 8 h for up to 14 doses) concurrently with IPI at weeks 4 and 7. After the first 12 weeks of combination therapy, maintenance IPI (10 mg/kg IV) monotherapy was administered every 12 weeks for up to 1 year. No patient had received prior PD-1 blockade, and only one received prior vemurafenib. Confirmed partial response was achieved in one (11%), stable disease in four (44%), and progressive disease in four (44%) of nine patients. Two patients achieved durable disease control of 44+ and 50+ months at the most recent follow-up without subsequent therapy. The median overall survival was not reached after a minimum 24 months of follow-up time. One-year and 2-year survival rates were 89 and 67%, respectively. Seven patients (78%) experienced grade 3 or 4 adverse events related to the study therapy, three of which were attributed to both agents. One patient discontinued the treatment due to liver and kidney toxicity. While toxicity was significant, all events were reversible, and there was no treatment-related mortality. In peripheral blood of patients with decreasing tumor burden, the ratio of the non-classical MHC-II proteins HLA-DM to HLA-DO increased 2-fold, raising the possibility of the ratio of HLA-DM:HLA-DO as a novel biomarker of response to treatment. Although the sample size was limited, combination therapy with high-dose IPI and high-dose IL-2 was feasible and associated with clinical benefit. IL-2-based compounds in combination with CTLA-4 blockade should be studied in advanced melanoma patients who fail to benefit from first-line PD-1 blockade
- …